Antinuclear Antibodies (ANA)

How to Cite This Chapter: Don-Wauchope A, Chetty VT, Ivica J, Kavsak P, Khan WI, Lafreniere M, Nouri K, Solnica B. Antinuclear Antibodies (ANA). McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. https://empendium.com/mcmtextbook/chapter/B31.1269.3.7.131. Accessed May 24, 2024.
Last Updated: May 9, 2022
Last Reviewed: May 9, 2022
Chapter Information

For a brief introduction and guide to abbreviations, see Laboratory Tests: General Remarks.

Analyte [material]

Antinuclear antibodies (ANA) [S/P]

Reference range, target level, or decision threshold

As provided by laboratory, depending on method!!!

Indirect immunofluorescence on HEp-2000: Titer <1:160

Interpretation of results

SLE, drug-induced lupus erythematosus, antiphospholipid syndrome, scleroderma, polymyositis and dermatomyositis, Sjögren syndrome, mixed connective tissue disease, rheumatoid arthritis, juvenile idiopathic arthritis, Raynaud phenomenon, other clinical conditions (where it is usually clinically insignificant) including infections (eg, TB, viral hepatitis, syphilis, parasitic diseases), malignancies (eg, breast cancer, prostate cancer, leukemia, Hodgkin lymphoma), liver and pulmonary diseases, skin diseases (eg, psoriasis, lichen planus), solid organ transplant, use of certain drugs (particularly hydralazine), other autoimmune conditions (eg, primary cholangitis, Addison disease, Hashimoto thyroiditis, immune thrombocytopenic purpura, autoimmune hemolytic anemia, type 1 DM), HIV infection, healthy individuals

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.